Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal esketamine for treatment-resistant major depressive disorder
RBR-247s9qPhase 3Recruiting
- Sponsor
- Ruschel Medicina e Pesquisa Clínica
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of esketamine in major depressive disorder (MDD) (3 arms), sponsored by Ruschel Medicina e Pesquisa Clínica. Started Jun 2015; status: recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on RBR-247s9q.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-247s9q.